Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1988 4
1989 5
1990 8
1991 6
1992 9
1993 12
1994 12
1995 10
1996 10
1997 11
1998 10
1999 11
2000 22
2001 8
2002 7
2003 10
2004 9
2005 9
2006 15
2007 12
2008 18
2009 20
2010 14
2011 23
2012 18
2013 12
2014 24
2015 12
2016 7
2017 11
2018 11
2019 12
2020 11
2021 10
2022 10
2023 9
2024 12
2025 11
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

411 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M. Rosenberg R, et al. JAMA Netw Open. 2019 Dec 2;2(12):e1918254. doi: 10.1001/jamanetworkopen.2019.18254. JAMA Netw Open. 2019. PMID: 31880796 Free PMC article. Clinical Trial.
INTERVENTIONS: Participants received placebo, zolpidem tartrate extended release (6.25 mg), or lemborexant (5 mg or 10 mg) for 1 month at bedtime. ...Six participants (4 in the zolpidem group and 2 in the lemborexant 5 mg group) reported serious adverse events; none …
INTERVENTIONS: Participants received placebo, zolpidem tartrate extended release (6.25 mg), or lemborexant (5 mg or 10 mg) for 1 mont …
Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists: A Randomized Clinical Trial.
Fung CH, Alessi C, Martin JL, Josephson K, Kierlin L, Dzierzewski JM, Moore AA, Badr MS, Zeidler M, Kelly M, Smith JP, Cook IA, Der-Mcleod E, Ghadimi S, Naeem S, Partch L, Guzman A, Grinberg A, Mitchell M. Fung CH, et al. JAMA Intern Med. 2024 Dec 1;184(12):1448-1456. doi: 10.1001/jamainternmed.2024.5020. JAMA Intern Med. 2024. PMID: 39374004 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial conducted at an academic medical center and a Department of Veterans Affairs medical center included adults aged 55 years or older who had used lorazepam, alprazolam, clonazepam, temazepam, and/or zolpidem f …
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial conducted at an academic medical center and a Department of Veterans Affai …
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.
Dauvilliers Y, Zammit G, Fietze I, Mayleben D, Seboek Kinter D, Pain S, Hedner J. Dauvilliers Y, et al. Ann Neurol. 2020 Mar;87(3):347-356. doi: 10.1002/ana.25680. Epub 2020 Feb 5. Ann Neurol. 2020. PMID: 31953863 Clinical Trial.
METHODS: Adults ( 64 years) with insomnia disorder were randomized (1:1:1:1:1:1) to receive daily oral placebo, daridorexant (5, 10, 25, or 50mg), or 10mg zolpidem for 30 days. The primary efficacy outcome was the change in wake time after sleep onset from baseline to days …
METHODS: Adults ( 64 years) with insomnia disorder were randomized (1:1:1:1:1:1) to receive daily oral placebo, daridorexant (5, 10, 25, or …
Zolpidem extended-release.
Moen MD, Plosker GL. Moen MD, et al. CNS Drugs. 2006;20(5):419-26; discussion 427-8. doi: 10.2165/00023210-200620050-00006. CNS Drugs. 2006. PMID: 16696581 Clinical Trial.
Zolpidem extended-release, or controlled-release (CR), is a new formulation of zolpidem, a nonbenzodiazepine hypnotic. It is indicated in the US for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance. Zolpidem C …
Zolpidem extended-release, or controlled-release (CR), is a new formulation of zolpidem, a nonbenzodiazepine hypnotic. It is i …
Effect of Psychological and Medication Therapies for Insomnia on Daytime Functions: A Randomized Clinical Trial.
Morin CM, Chen SJ, Ivers H, Beaulieu-Bonneau S, Krystal AD, Guay B, Bélanger L, Cartwright A, Simmons B, Lamy M, Busby M, Edinger JD. Morin CM, et al. JAMA Netw Open. 2023 Dec 1;6(12):e2349638. doi: 10.1001/jamanetworkopen.2023.49638. JAMA Netw Open. 2023. PMID: 38153735 Free PMC article. Clinical Trial.
INTERVENTIONS: Participants were randomly assigned to either BT or zolpidem as first-stage therapy, and those whose insomnia had not remitted received a second-stage psychological therapy (BT or cognitive therapy) or medication therapy (zolpidem or trazodone). ...Se …
INTERVENTIONS: Participants were randomly assigned to either BT or zolpidem as first-stage therapy, and those whose insomnia had not …
Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials.
Gotfried MH, Auerbach SH, Dang-Vu TT, Mishima K, Kumar D, Moline M, Malhotra M. Gotfried MH, et al. Drugs Aging. 2024 Sep;41(9):741-752. doi: 10.1007/s40266-024-01135-8. Epub 2024 Aug 9. Drugs Aging. 2024. PMID: 39120786 Free PMC article. Clinical Trial.
METHODS: Study E2006-G000-304 (Study 304; NCT02783729) was a randomized, double-blind, placebo (PBO)-controlled, active-comparator trial where subjects with insomnia disorder received LEM 5 mg (LEM5), LEM 10 mg (LEM10), zolpidem tartrate extended-release 6.25 mg (ZOL), or …
METHODS: Study E2006-G000-304 (Study 304; NCT02783729) was a randomized, double-blind, placebo (PBO)-controlled, active-comparator trial whe …
Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study.
Ozone M, Hirota S, Ariyoshi Y, Hayashida K, Ikegami A, Habukawa M, Ohshima H, Harada D, Hiejima H, Kotorii N, Murotani K, Taninaga T, Uchimura N. Ozone M, et al. Adv Ther. 2024 Apr;41(4):1728-1745. doi: 10.1007/s12325-024-02811-2. Epub 2024 Mar 9. Adv Ther. 2024. PMID: 38460107 Free PMC article. Clinical Trial.
This prospective, non-randomized, open-label, interventional, multicenter study assessed whether Japanese patients with chronic insomnia dissatisfied with treatment could transition directly to lemborexant (LEM) from four cohorts-non-benzodiazepine sedative-hypnotic (zolpidem …
This prospective, non-randomized, open-label, interventional, multicenter study assessed whether Japanese patients with chronic insomnia dis …
Effect of lemborexant on sleep architecture in participants with insomnia disorder and mild obstructive sleep apnea.
Kushida CA, Zammit GK, Cheng JY, Kumar D, Moline M. Kushida CA, et al. Sleep Med. 2025 Mar;127:170-177. doi: 10.1016/j.sleep.2024.12.023. Epub 2024 Dec 17. Sleep Med. 2025. PMID: 39879708 Free article. Clinical Trial.
PATIENTS/METHODS: E2006-G000-304 was a phase 3, one-month polysomnography trial in adults aged 55 years with insomnia receiving LEM 5 mg (LEM5) or 10 mg (LEM10), placebo (PBO), or zolpidem-tartrate-extended-release 6.25 mg (ZOL). Sleep architecture was determined from 2 n …
PATIENTS/METHODS: E2006-G000-304 was a phase 3, one-month polysomnography trial in adults aged 55 years with insomnia receiving LEM 5 mg (L …
Zolpidem improves task-specific dystonia: A randomized clinical trial integrating exploratory transcranial magnetic stimulation and [18F] FDG-PET imaging.
Vogelnik Žakelj K, Trošt M, Tomše P, Petrović IN, Tomić Pešić A, Radovanović S, Kojović M. Vogelnik Žakelj K, et al. Parkinsonism Relat Disord. 2024 Jul;124:107014. doi: 10.1016/j.parkreldis.2024.107014. Epub 2024 May 17. Parkinsonism Relat Disord. 2024. PMID: 38823169 Free article. Clinical Trial.
Eight patients underwent brain FDG-PET imaging on zolpidem and placebo. RESULTS: Zolpidem treatment improved TSFD. Zolpidem compared to placebo flattened rest and active input/output curves, reduced ICF and was associated with hypometabolism in the right cere …
Eight patients underwent brain FDG-PET imaging on zolpidem and placebo. RESULTS: Zolpidem treatment improved TSFD. Zolpidem …
Blinding and bias in a hypnotic clinical trial.
McCall WV, Benca RM, Rumble ME, Krystal AD. McCall WV, et al. Hum Psychopharmacol. 2021 Jan;36(1):1-5. doi: 10.1002/hup.2757. Epub 2020 Sep 11. Hum Psychopharmacol. 2021. PMID: 32918323 Clinical Trial.
METHODS: REST-IT, a, 8-week double-blind RCT, compared zolpidem extended-release (ER) versus placebo at bedtime in 103 adults with major depressive disorder with insomnia and suicidal ideation, and who received open label selective serotonin reuptake inhibitors. ...CONCLUS …
METHODS: REST-IT, a, 8-week double-blind RCT, compared zolpidem extended-release (ER) versus placebo at bedtime in 103 adults with ma …
411 results